Aspire BioPharma, Inc. Cash Flow Conversion Efficiency
Aspire BioPharma, Inc. cash flow conversion efficiency. Based on the latest financial reports, Aspire BioPharma, Inc. (ASBP) has a cash flow conversion efficiency ratio of -0.180x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.12 Million) by net assets ($11.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aspire BioPharma, Inc. (2021–2025)
Cash flow conversion efficiency of Aspire BioPharma, Inc. from 2021 to 2025. This chart illustrates how Aspire BioPharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Aspire BioPharma, Inc. stock price for real-time trading data and today's change.
Aspire BioPharma, Inc. Cash Flow Conversion Ratio Explained
Aspire BioPharma, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aspire BioPharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aspire BioPharma, Inc. ranked by their cash flow conversion efficiency. Also see ASBP company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The House of Agriculture Spiroy S.A.
AT:SPIR
|
0.757x |
|
Medicus Pharma Ltd. Common Stock
NASDAQ:MDCX
|
4.078x |
|
ECOUP OYJ EO 1
F:62H
|
N/A |
|
Pivotal Metals Ltd
AU:PVT
|
-0.038x |
|
Boa Concept SA
PA:ALBOA
|
0.010x |
|
REC Silicon ASA
OL:RECSI
|
0.174x |
|
ABM Fujiya Bhd
KLSE:5198
|
0.071x |
|
Larq SA
WAR:LRQ
|
0.001x |
Annual Cash Flow Conversion Efficiency for Aspire BioPharma, Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Aspire BioPharma, Inc. from 2021 to 2025. Review how much free cash does Aspire BioPharma, Inc. generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-6.38 Million | $-4.92 Million | 0.772x | +348.43% |
| 2024-12-31 | $-1.54 Million | $-265.19K | 0.172x | +616.19% |
| 2023-12-31 | $19.58 Million | $-653.11K | -0.033x | -6647.49% |
| 2022-12-31 | $289.07 Million | $-142.91K | 0.000x | -100.09% |
| 2021-12-31 | $-475.00 | $-260.00 | 0.547x | -- |
About Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually admi… Read more